Ratings Wilmington plc

Equities

WIL

GB0009692319

Market Closed - London S.E. Other stock markets 16:35:24 02/05/2024 BST			5-day change	1st Jan Change
364 ^GBX	-2.93%		+1.11%	+9.64%

04-26	Wilmington sells French healthcare business APM for EUR26 million	AN
04-26	Wilmington Sells French Healthcare Unit for EUR26 million	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Analysts covering this company mostly recommend stock overweighting or purchase.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

In relation to the value of its tangible assets, the company's valuation appears relatively high.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Consumer Publishing

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
WILMINGTON PLC	+9.64%	418M		C+
PEARSON PLC	+1.06%	8.13B		A
SCHIBSTED ASA	+8.75%	6.39B		B
SAUDI RESEARCH AND MEDIA GROUP	+40.49%	5.1B	-	-
JIANGSU PHOENIX PUBLISHING & MEDIA CORPORATION LIMITED	+15.78%	3.59B		D-
LAGARDÈRE S.A.	+14.53%	3.17B		B+
CHINA SOUTH PUBLISHING & MEDIA GROUP CO., LTD	+19.08%	3B		C-
KADOKAWA CORPORATION	-2.23%	2.44B		-
SOUTHERN PUBLISHING AND MEDIA CO.,LTD.	+13.47%	1.8B		-
CHANGJIANG PUBLISHING & MEDIA CO.,LTD	+1.34%	1.27B	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes